BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18221103)

  • 1. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the "Coagulation Defects" AIEOP Working Group.
    Giordano P; Del Vecchio GC; Saracco P; Zecca M; Molinari AC; De Mattia D;
    Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):53-62. PubMed ID: 18221103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
    Greiner J; Schrappe M; Claviez A; Zimmermann M; Niemeyer C; Kolb R; Eberl W; Berthold F; Bergsträsser E; Gnekow A; Lassay E; Vorwerk P; Lauten M; Sauerbrey A; Rischewski J; Beilken A; Henze G; Korte W; Möricke A;
    Haematologica; 2019 Apr; 104(4):756-765. PubMed ID: 30262570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
    Andersson NG; Rathe M; Mølle I; Jarvis KB; Hoffmann M; Huurre A; Joelsson J; Albertsen BK; Lohi O; Långström S; Overgaard U; Saulyte Trakymiene S; Vepsäläinen K; Vogt H; Ranta S
    Br J Haematol; 2022 Oct; 199(1):117-121. PubMed ID: 35922061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin in pediatric patients.
    Sutor AH; Chan AK; Massicotte P
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Monagle P; Chan A; Massicotte P; Chalmers E; Michelson AD
    Chest; 2004 Sep; 126(3 Suppl):645S-687S. PubMed ID: 15383489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin in children.
    Albisetti M; Andrew M
    Eur J Pediatr; 2002 Feb; 161(2):71-7. PubMed ID: 11954754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.
    Santoro N; Colombini A; Silvestri D; Grassi M; Giordano P; Parasole R; Barisone E; Caruso R; Conter V; Valsecchi MG; Masera G; Rizzari C
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):348-55. PubMed ID: 23619106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the outcomes associated with periprocedural anticoagulation management in children with acute lymphoblastic leukemia.
    Avila ML; Macartney CA; Hitzler JK; Williams S; Kiss A; Brandão LR
    J Pediatr; 2014 May; 164(5):1201-7. PubMed ID: 24582006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
    Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombophilia, thromboembolism and the use of the unfractionated and low-molecular-weight heparins].
    Lobato-Mendizábal E; Majluf-Cruz A
    Rev Invest Clin; 2000; 52(5):529-45. PubMed ID: 11195182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.
    Gould MK; Dembitzer AD; Doyle RL; Hastie TJ; Garber AM
    Ann Intern Med; 1999 May; 130(10):800-9. PubMed ID: 10366369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    van Der Heijden JF ; Hutten BA; Büller HR; Prins MH
    Cochrane Database Syst Rev; 2000; (4):CD002001. PubMed ID: 11034739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Venous thrombosis--a diagnostic and therapeutic challenge].
    Spengel FA; von Liebe S
    Radiologe; 1998 Jul; 38(7):549-53. PubMed ID: 9738258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of thrombotic complications in acute lymphoblastic leukemia.
    Zia AN; Chitlur M
    Indian J Pediatr; 2013 Oct; 80(10):853-62. PubMed ID: 23912824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.